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Uterine adenomyosis and/or adenomyoma is characterized by the presence of heterotopic endometrial
glands and stroma within the myometrium, >2.5 mm in depth in the myometrium or more than one
microscopic ﬁeld at 10 times magniﬁcation from the endometriumemyometrium junction, and a vari-
able degree of adjacent myometrial hyperplasia, causing globular and cystic enlargement of the myo-
metrium, with some cysts ﬁlled with extravasated, hemolyzed red blood cells, and siderophages.
Hysterectomy is a “gold standard” and deﬁnitive therapy for uterine adenomyosis, and many cases of
adenomyosis have been diagnosed by pathological review retrospectively. As such, the diagnosis of
adenomyosis is difﬁcult, and this subsequently results in difﬁculty in the management of these patients,
especially those who are symptomatic but have a strong desire to preserve their uterus. In our previous
review, we found that the use of uterine-sparing surgery in the management of uterine adenomyosis
and/or adenomyoma is still controversial, although some data support its feasibility. Conservative
treatment is still needed in the group of patients that requires preservation of fertility and improvement
of quality of life. However, studies focusing on the topic of medical treatment for adenomyosis are rare. In
this article, current knowledge regarding the use of medical therapy for uterine adenomyosis, partly
based on the understanding of endometriosis, is reviewed.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Uterine adenomyosis was ﬁrst reported in the 19th century and
early 20th century; von Rokitansky [1] described it in 1860 andf the Taiwan Association of
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bstetrics & Gynecology. PublishedFrankl [2] later deﬁned it as adenomyosis interna. Since then, the
general clinical, pathological, and radiologic ﬁndings and poten-
tially useful management methods have been reviewed in many
studies [3e16], including ours [17,18]. Feldele et al. [9] commented
that conservative surgical treatment is impracticable as it is not
possible to isolate the adenomyotic tissue adequately; therefore,
the authors suggested that hysterectomy is the only rational and
complete procedure. In our previous review [17], we found that
there is more evidence supporting the advantages of conservative
uterine-sparing surgery in providing not only more effective
symptom relief but also longer durable symptom control for
symptomatic women with uterine adenomyosis and/or adeno-
myoma, compared with medical treatment alone. Furthermore, the
effectiveness of conservative uterine-sparing surgery for adeno-
myosis was also promising, since the main problem secondary toby Elsevier Taiwan LLC. All rights reserved.
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by up to 80%; menorrhea was also improved in more than two-
thirds of patients after type I uterine-sparing surgery (complete
resection of adenomyosis, also called adenomyomectomy), and half
of the patients saw beneﬁt in symptom control after type II con-
servative uterine-sparing surgery (conservative cytoreductive
uterine-sparing surgery) [18]. In addition, there was no negative
impact on reproductive performance after conservative uterine-
sparing surgery, and, in fact, reproductive performance seemed to
be improved compared with that after medical treatment; not only
was there a higher cumulative pregnancy rate, but also a higher
cumulative ﬁnal successful delivery rate. That is why Vercellini
et al. [19] commented that lesion eradication is a fertility-
enhancing procedure. However, there is no doubt that the data
supporting the above-mentioned beneﬁts for symptomatic women
with uterine adenomyosis after conservative uterine-sparing sur-
gery are limited, suggesting that the beneﬁt may be moderate. In
fact, one of the main indications for surgery is temporary pain relief
in women seeking spontaneous conception. In addition, the effect
of surgery on pain is usually only temporarily satisfactory, and the
risk of complications varies according to the type of lesion extir-
pated. In light of this, greater understanding of the pathophysiology
of adenomyosis might be very important, and might help us
manage these patients in the future.
Pathophysiology of adenomyosis
The need for hysterectomy to diagnose adenomyosis means that
many cases go undetected, and limits our understanding of the
prevalence and clinical impact [20]. There is no agreement that the
histological diagnosis can be made, since the depth of myometrial
invasion ranges from 0.5 cm to>25% of the myometrial thickness in
one high power ﬁeld, although adenomyosis-related symptoms
may not correlate with the depth of invasion [21]. In addition, there
is no universally accepted classiﬁcation of adenomyosis, even
though Reinhold et al. [22] deﬁned the criteria as the presence of
endometrial tissue at  2.5 mm below the endomyometrial junc-
tion and a thickness of the junction zone of 12 mm. Brosens et al.
[23] suggested that adenomyosis is a dichotomous disease that is
characterized by disruption of the inner myometrial architecture
and function, with secondary inﬁltration of endometrial elements
into the myometrium. As early as 2002 [24], we attempted to
analyze genetic aberrations in uterine adenomyosis using
comparative genomic hybridization; however, we failed to detect
any signiﬁcant genomic ampliﬁcation or deletion. The possible
causes include difﬁculties speciﬁcally related to adenomyosis: that
the tissue studied was complicated by a mixture of epithelial and
stromal cells in addition to normal myometrial tissue. In addition,
there may have been a surplus of normal myometrial tissue in the
prepared tissue vs. the adenomyosis tissue. We suggested that
special procedures, such as laser-assisted microdissection, and
appropriate ampliﬁcation of DNA by degenerate oligonucleotide-
primed polymerase chain reaction, may offer the opportunity to
investigate sequence copy number changes in small, morphologi-
cally well-deﬁned groups of lesions [24]. Of course, the predomi-
nantly normal karyotype seen in adenomyosis may be due to the
resolution limits of karyotyping, with any changes present being
submicroscopic. The years have passed, and recent evidence sup-
ports adenomyosis, which includes an abnormal gene expression,
increased angiogenesis and proliferation, decreased apoptosis,
impaired cytokine expression, local estrogen production, resistance
to progesterone, and increased nerve density, immunological
stress, and oxidative stress [20]. Today, the real challenge is
tailoring treatment to personal needs, depending on the type and
extent of disease. The following sections are a summary of therecent knowledge of useful medications and results for patients
with adenomyosis and/or adenomyoma after medical treatment.
Medical treatment
Medical treatments for adenomyosis always follow the princi-
ples of the management of endometriosis, which are usually aimed
at reducing the production of endogenous estrogen or inducing
endometrial differentiation with progestins. Clinical evidence
points to the clear and deleterious effect of uninterrupted ovulatory
cycles on the development and persistence of adenomyosis;
symptoms of adenomyosis usually appear after menarche and
vanish after menopause. The objectives of medical treatment are
the inhibition of ovulation, abolition of menstruation, and
achievement of a stable steroid hormone milieu, based on the
concept that the responses of the eutopic and ectopic endometria
are substantially similar [19]. Medical therapies commonly used in
the treatment of adenomyosis, similar to those for endometriosis,
are mainly based on the fact that the hypothal-
amicepituitaryegonadal axis plays a pivotal role in every phase of
mammalian reproduction, and include gonadotropin-releasing
hormone agonist (GnRH agonist), oral contraceptives (OCs), pro-
gestins, danazol, and recently, selective estrogen receptor modu-
lators (SERMs), selective progesterone receptor modulators
(SPRMs) or aromatase inhibitors (AIs). These agents create a
hypoestrogenic (GnRH agonists, AIs), hyperandrogenic (danazol,
gestrinone), or hyperprogestogenic (OCs, progestins) environment,
with suppression of endometrial cell proliferation [19]. However,
medical treatments are symptomatic and not cytoreductive: lesions
survive the use of any drug, at any dose, for any length of time, and
are ready to resume their metabolic activity at treatment discon-
tinuation [19]. Medical treatments may represent standard thera-
pies for adenomyosis and are associated with adverse events
impacting long-term use and adherence. Since no medical treat-
ment for endometriosis is universally effective, we should
emphasize that this concept is also applicable to adenomyosis
therapy. Therefore, parts of the following data are based on studies
of endometriosis.
SERMs
Basic clinical studies indicate major roles for estrogen and pro-
gesterone in the pathology of adenomyosis. Our previous study
proposed that the estrogen-induced epithelialemesenchymal
transition (EMT) in endometrial epithelial cells contributes to the
development of adenomyosis based on the following evidence: (1)
E-cadherine was downregulated and vimentin was upregulated in
the epithelial compartment of adenomyotic lesions; (2) changes in
EMT markers were associated with the serum estradiol (E2) levels;
(3) estrogen induced EMT migration, and invasion of estrogen re-
ceptor (ER)-positive endometrial cells, and such effects were
abrogated by a SERM; and (4) estrogen-dependent adhesion of
xeno-transplanted endometrial fragments to the peritoneal cavities
of mice was observed, suggesting that SERMs may be a potential
therapeutic agent for adenomyosis patients [25]. The ﬁnding that
SERMs [26e30], including clomiphene, tamoxifen, toremifene,
raloxifene, ospemifene, lasofoxifene, bazedoxifene, and bazedox-
ifene/conjugated estrogen, have tissue-speciﬁc agonisteantagonist
activity led to the realization that the classic model was incomplete
and that estrogen actionwas more complex than had been thought.
The mechanisms of the tissue-selective, mixed agonisteantagonist
action of SERMs can be explained by three interactive mechanisms,
including differential ER expression in a given target tissue, dif-
ferential ER conformation on ligand binding, and differential
expression and binding to the ER coregulator proteins (Table 1),
Table 1
Mechanisms of candidate drugs for treatment in women with endometriosis and/or adenomyosis.
Drugs Mechanisms
Selective ER modulator (tamoxifen, toremifene, raloxifene, ospemifene,
lasofoxifene, and bazedoxifene)
(1) Differential ER expression in a given target tissue
(2) Differential ER conformation on ligand binding
(3) Differential expression and binding to the ER coregulator proteins
ER inhibitor (fulvestrant) Complete blockade of estrogen action, resulting in impaired dimerization,
increased turnover, and disrupted nuclear localization
Selective PR modulator (ulipristal acetate, mifepristone, asoprisnil, lonaprisan,
telapristone acetate, PRA-910, ZK 136799, and onapristone)
(1) Differential PR expression in a given target tissue
(2) Differential PR conformation on ligand binding
(3) Differential expression and binding to the PR coregulator proteins
Progestins Action involves decidualization and subsequent atrophy of endometrial tissue
Gestrinone (1) A progestational withdrawal effect at the endometrial cellular level
(2) Inhibition of ovarian steroidogenesis
Aromatase inhibitor Inhibition of the estradiol synthesis
Type I: suicidal or noncompetitive
Type II: competitive
Oral contraceptives (1) Decrease of retrograde menstruation (the maximal effect occurs when
given continuously)
(2) Induction of a pseudo-pregnant status, which causes decidualization and
subsequent atrophy of the endometrium
Danazol Androgenic and hypoestrogenic environment
Levonorgestrel-releasing intrauterine system May be mediated through a slow-release progestin
Gonadotropin-releasing hormone agonists Downregulation of gonadotropin releasing hormone
ER ¼ estrogen receptor; PR ¼ progesterone receptor.
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with adenomyosis [31e33]. In a mouse model, SERM-treated ani-
mals consistently demonstrated decreased endometriosis lesion
size compared to vehicle-treated animals [34]. In addition,
macroscopic analysis showed that there were no signs of active
endometriotic implants in SERM-treated animals, and histological
examination showed diminished glands and a decrease in luminal
cell height as a consequence of SERM treatment [34]. For the
treatment of adenomyosis, the ideal SERM might be one that has
antagonistic activity in the endometrium (adenomyotic lesion) and
agonistic activity for bone and lipids [26,27]. Stratton and col-
leagues [35] pioneered the evaluation of whether 6 months of
SERM was effective in treating chronic pelvic pain in women with
endometriosis, but the Data Safety Monitoring Committee termi-
nated the study early when the SERM group experienced pain
(p ¼ 0.03) and had a second surgery (p ¼ 0.16) signiﬁcantly sooner
than the controls. However, biopsy-proved endometriosis was not
associated with the return of pain (p ¼ 0.6), suggesting that other
factors are implicated in pelvic pain [35]. Further studies using
SERMs and possibly other medical therapies may identify an ideal
agent for the treatment of adenomyosis.
SPRMs or progestins
The role of progesterone in the development or persistence of
adenomyosis is not clear for the following reasons: (1) the pro-
tective role of progesterone in endometrial cancer [36,37] is not
completely applicable to adenomyosis, since adenomyosis is not
pure epithelial proliferation but rather increased inﬂammation and
cell survival due to diminished apoptosis or differentiation; (2)
progesterone induces a transient proliferation of stromal cells in
normal endometrium; (3) only half of patients with adenomyosis
beneﬁt from progesterone therapy; (4) antiprogestins with mixed
agonist and antagonist properties (SPRM) reduce adenomyosis-
associated pelvic pain, possibly more effectively than progestins;
although the reason is not clear, it may be secondary to proges-
terone resistance in adenomyosis; and (5) adenomyotic lesions
produce signiﬁcant quantities of progesterone and contain strik-
ingly lower levels of progesterone receptor (PR) with endometrium
[38,39]. SPRMs interact with the PR, allowing the binding of PR
dimers to target gene promoters [38e43]. Similar to SERM on ERs,the conformation induced by each SPRM promotes the interaction
of PR with both coactivators and corepressors (Table 1), leading to
mixed agonisteantagonist activity depending on their structure
and the relative tissue concentrations of these comodulators. Evi-
dence has shown that SPRMs, including ulipristal acetate, mife-
pristone, asoprisnil, lonaprisan, telapristone acetate, PRA-910, ZK
136799, and onapristone, inhibit endometrial proliferation or
suppress adenomyotic lesions, resulting in inhibition of prosta-
glandin production and endometrial atrophy in animalmodels [40].
In addition, a small number of clinical studies have also demon-
strated that SPRMs have potential in the treatment of adenomyosis.
For example, taking 50-mg of mifepristone daily has been shown to
improve pain and cause regression of adenomyosis [41], asoprisnil
and telapristone acetate have also been reported to relieve
adenomyosis-associated pain [42,43], suggesting that these bene-
ﬁcial effects of SPRM treatment may reﬂect changes in the endo-
metrial morphology and/or the absence of bleeding, although the
potential consequences of SPRM-associated endometrial change
remain unknown and the effect of long-term treatment with
SPRMs needs further determination.
Progestins and antiprogestins (gastrinone)
A Cochrane database systematic review showed that the pro-
gestagen or progesins medroxyprogesterone acetate (100 mg
medroxyprogesterone (MPA) daily) appeared to be more effective
at reducing all symptoms up to 12 months of follow-up (mean
difference 0.70, 95% conﬁdence interval 8.61 to 5.39;
p < 0.00001) compared with placebo (moderate-quality evidence)
[44,45]; however, there was evidence of signiﬁcantly more cases of
side effect, such as acne and edema in the MPA group compared
with placebo [44]. Norethisterone acetate (2.5 mg per day) is
associated with a marked degree of pain relief and satisfactionwith
treatment after 1 year, although the efﬁcacy seems to be more
gradual, but progressively better with a longer duration of use [19].
A drawback of progestin therapy is the reduction of libido in about
one-ﬁfth of women [19]. Compared with other medical treatment,
amenorrhea and bleeding were more frequently reported in the
progestin group; in addition, the depot progestagen group experi-
enced signiﬁcantly more adverse effects [44]. All suggest that only
limited evidence to support the use of progestagens for
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randomized clinical trials addressing quality of life had a high
withdrawal rate [45]. Gestrinone (ethylnorgestrienone, R2323) is
an antiprogestational steroid used in Europe and Taiwan for the
treatment of endometriosis, which is administered orally with
doses ranging from 2.5 mg to 10 mg, administered daily to weekly
[46]. The mechanism of action includes a progestational with-
drawal effect at the endometrial cellular level and inhibition of
ovarian steroidogenesis [46]. Side effects relate to both androgenic
and antiestrogenic effects, and there was no evidence of a beneﬁt of
gestrinone compared with danazol [44]. In addition, the thera-
peutic effects of gestrinone for dysmenorrhea were signiﬁcantly
worse than those of GnRH agonist [44].
AIs
Aromatase is the enzyme responsible for the transformation of
androgens, androstenedione, and testosterone, into estrogens,
estrone, and E2, respectively [47]. Aromatase enzyme is comprised
of two polypeptides, a speciﬁc cytochrome P450 (product of the
CYP19 gene), and ﬂavoprotein, nicotinamideeadenine dinucleotide
phosphatate cytochrome P450 reductase [48]. Aromatase is an
excellent target for inhibition of the E2 synthesis because it is the
ﬁnal step in steroid biosynthesis; therefore, there are no important
downstream enzymes to be affected. Due to the molecular obser-
vations of increased expression of aromatase P450 in adenomyotic
lesion published during the past 10 years, the number of clinical
trials employing AIs in the management of endometriosis and/or
adenomyosis has increased strikingly since 2004 [49,50]. AIs are
classiﬁed into type I inhibitors (suicidal or noncompetitive) and
type II inhibitors (competitive), and both compete for binding to
the active site [48]. Once a type I inhibitor has worked, the enzyme
initiates hydroxylation, producing an unbreakable bond between
the inhibitor and the enzyme protein, resulting in permanent
blockage; type II inhibitors work in a reverse manner on the active
enzyme site without triggering enzyme activity. However, the in-
hibition can disassociate from the binding site, allowing renewed
competition between the inhibitor and the substrate for binding to
this active site; therefore, a constant presence of the type II in-
hibitor is needed to continue the effect, and the effectiveness de-
pends on the afﬁnities of the inhibitor and the substrate [48].
Ferrero et al. [51] performed a systematic review to assess the ef-
ﬁcacy of AI in treating endometriosis-related pain, especially
focusing on type II nonsteroidal AI, such as anastrozole and letro-
zole, and analyzed a total of 251 women from 10 studies, including
ﬁve prospective noncomparative studies, four randomized
controlled trials, and one patient preference study. All the obser-
vational studies demonstrated that AIs combined with either pro-
gestins or OC reduced the severity of endometriosis-related pain
and improved quality of life; however, some studies showed a high
incidence of adverse effects and no improvement of patient satis-
faction, or a recurrence of symptoms after discontinuation of
treatment, suggesting future investigations should clarify whether
the long-term administration of AIs is superior to currently avail-
able medical therapies in terms of improvement of pain, adverse
effects, and patient satisfaction [51].
OCs
The reasons for using OC in the management of adenomyosis
include: (1) a decrease in retrograde menstruation (the maximal
effect occurs when given continuously); and (2) induction of a
pseudo-pregnant status, which causes decidualization and subse-
quent atrophy of the endometrium [19]. All OCs have been asso-
ciated with an increased risk of venous thrombosis, and the effectsize depended both on the progestins used and the dose of ethinyl
E2, suggesting that combining different preparations of OC into
generations of progestogens may not be an appropriate way to
prevent the risk of thrombosis [52]. In addition, no differences have
been demonstrated between various OCs, and this has led to the
use of preparations with the least possible estrogen content to
prevent adverse events. Monophasic, low-dose OC shows overall
safety, good efﬁcacy, appreciable tolerability and low cost, and may
be the best choice for adenomyosis-related pain (dysmenorrhea);
continuous use is suggested, with the aim of abolishing uterine
ﬂows [19]. Medical therapy with OC enables satisfactory long-term
pain control in two-thirds of women with symptomatic endome-
triosis and/or adenomyosis [19]. Combined OC increased irregular
uterine bleeding (60% vs. 26%) and nausea (24% vs. 0%) compared
with placebo [45].Danazol
Danazol is an isoxazol derivative of 12 a-ethinyl testosterone,
and has a complex mechanism of action involving inhibiting ste-
roidogenesis, lowering the mid-cycle luteinizing hormone surge,
and increasing serum free testosterone levels [53]. Danazol use
results in an androgenic and hypoestrogenic environment; the
former might have a more direct effect on adenomyotic lesions and
reduce pain during and after therapy, and the latter may have an
indirect effect on adenomyotic lesions [53], contributing to
relieving pain and resulting in clinical improvement in 55e93% of
women treated for 6 months [54]. However, danazol and ges-
trinone are not suitable for prolonged use, partly because of their
androgenic side effects, including seborrhea, hypertrichosis, and
increased body weight, and the risk of metabolic syndrome, such as
their unfavorable effects on serum cholesterol lipoprotein distri-
bution (decreased high-density lipoprotein and increased low-
density lipoprotein).Levonorgestrel-releasing intrauterine system
Although the levonorgestrel-releasing intrauterine system
(LNG-IUS) is not Food and Drug Administration-approved for the
treatment of endometriosis-related pain, evidence supports its use
as an effective alternative treatment, since it abolishes menstrua-
tion in one-third of women and substantially decreases the amount
of bleeding in another third [19]. One longitudinal contraception
study evaluated the prevalence and severity of dysmenorrhea after
the use of different kinds of intrauterine contraception methods
and the data showed that use of a copper intrauterine device did
not inﬂuence the severity of dysmenorrhea, but the LNG-IUS was
shown to reduce the severity of dysmenorrhea signiﬁcantly; the
study did not provide information on the diagnosis or treatment of
endometriosis and adenomyosis, but suggested the efﬁcacy of LNG-
IUS in reducing dysmenorrhea [55]. In addition, a recent review
offered the good news that physicians have an array of viable
treatment options available to treat the distressing condition of
heavy menstrual bleeding, which is often secondary to uterine
adenomyosis [56]. LNG-IUS reduces abnormal uterine bleeding
secondary to endometrial dysfunction more than OC, luteal-phase
oral progestins, or nonsteroidal anti-inﬂammatory drugs, and that
antiﬁbrinolytics are more effective than placebo [57]. In addition,
one randomized clinical trial found no signiﬁcant difference be-
tween LNG-IUS and the depot gonadorelin analog, leuprorelin in
reduction of visual analog scale (VAS) for endometriosis- and/or
adenomyosis-related pain throughout the 6 months' treatment
(post-treatment change in VAS scores not speciﬁed; p > 0.600 for
the difference in VAS change) [58].
Table 2
Summary of outcomes of women with adenomyosis and/or adenomyoma after medical treatment.
Drugs Symptom controla Adverse events
SERM Unsatisfactory Well-tolerated, hot ﬂush, leg cramp, hypercoagulation status
SPRM Good to excellent Well-tolerated, headache, nausea, fatigue and dizziness
Progestins Good to excellent Irregular bleeding, nausea/vomiting, mood swings, hot ﬂush, increased body weight
Gestrinone Good Seborrhea, hypertrichosis, and increased body weight, and the risk of metabolic syndrome,
such as unfavorable effects on serum cholesterol lipoprotein distribution
AI Unsatisfactory to fair Frequent and intolerable hypoestrogenic side effects, including vasomotor syndrome, genital
atrophy and mood instability, and a negative impact on bone health, also possible bad inﬂuence
on cardiovascular health
OC Good to excellent Irregular bleeding, hypercoagulation status, nausea/vomiting, headache
Danazol Good to excellent Seborrhea, hypertrichosis and increased body weight, and the risk of metabolic syndrome, such as
unfavorable effects on serum cholesterol lipoprotein distribution
LNG-IUS Excellent Irregular bleeding, abdominal pain
GnRH-a Excellent Frequent and intolerable hypoestrogenic side effects, including vasomotor syndrome, genital atrophy
and mood instability, and a negative impact on bone health, also possible bad inﬂuence on cardiovascular health
AI ¼ aromatase inhibitor; GnRH-a ¼ gonadotropin-releasing hormone agonist; LNG-IUS ¼ levonorgestrel-releasing intrauterine system; OC ¼ oral contraceptives;
SERM ¼ selective estrogen receptor modulator; SPRM ¼ selective progesterone receptor modulator.
a Symptom control: unsatisfactory (exacerbation or improvement <25%); fair (improvement 25e50%); good (improvement 50e75%); and excellent (improvement >75%).
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Since the hypothalamicepituitaryegonadal axis plays a pivotal
role in every phase of mammalian reproduction, and is also the
main cause of uterine adenomyosis, GnRH agonists are target drugs
for the treatment of adenomyosis. The GnRH decapeptide was
isolated and its structure elucidated in 1971 [59]. Amino acid sub-
stitutions have revealed the signiﬁcance of speciﬁc regions for
stability, receptor binding and activation of the pituitary gonado-
trophs, and modiﬁcations mainly at positions 6 and 10 gave rise to
analogs with increased potency, extending the half-life from mi-
nutes to hours and raising the binding capacity more than 100-fold
[59e62]. GnRH agonists are very effective against adenomyosis-
related pain, and thereby also contribute to the occurrence of
many successful pregnancies and live deliveries [63e67]. However,
the use of GnRH agonists is associated with frequent and intoler-
able hypoestrogenic side effects, including vasomotor syndrome,
genital atrophy, and mood instability; it also has a negative impact
on bone health and a possible negative inﬂuence on cardiovascular
health. In addition, GnRH agonists might be the most costly med-
ications available for the treatment of adenomyosis. To minimize
the GnRH agonist-inducing adverse events, an add-back therapy
with various kinds of hormone preparations has been successfully
used recently and enables an indeﬁnite extension of the GnRH
agonist treatment period. However, overall costs have continued to
increase. Therefore, some authors suggest that GnRH agonist plus
add-back therapy is used only in highly selected women unre-
sponsive to other medications or in surgically high-risk patients.
ER inhibitor
Fulvestrant (Faslodex; AstraZeneca, London, UK), a potent pure
antiestrogen with high afﬁnity binding with ER, was approved by
the US Food and Drug Administration in 2002 for the treatment of
hormonal receptor positive metastatic breast cancer [68]. Fulves-
trant completely attenuates the ability of the ER to activate or
inhibit transcription in a ligand-dependent or independent
manner, resulting in a blockade of estrogen action. Although a
Phase-II trial on the use of fulvestrant for treating endometriosis
was launched, there are no published data yet, suggesting that the
trial was terminated, probably due to an efﬁcacy issue or unac-
ceptably high risk/beneﬁt ratio [68]. Guo and Olive [68] suggested
that: (1) it is necessary to better understand the mechanisms of
endometriosis (adenomyosis) pathogenesis through more basicresearch; and (2) human endometriosis (adenomyosis) trials have
different endpoints than animal studies.Conclusion
For adenomyosis, the goal of therapy is important, and can
include symptom relief and possibly increased fertility. The results
of systematic literature reviews have consistently demonstrated
that, as long as amenorrhea is obtained, there are no statistical
differences between the various available drugs in terms of pain
relief, but tolerability, side effects, and costs vary widely [19]. The
therapeutic goal of medical treatment is not lesion resorption: le-
sions survive any drug, at any dose, for any period of use, and come
back at treatment discontinuation. Therefore, we should not
consider an inefﬁcacy of hormonal manipulation at drug discon-
tinuation. In addition, agents available for the management of
adenomyosis are mediated by creating a hypoestrogenic (GnRH
agonists, AIs), hyperandrogenic (danazol, gestrinone), or hyper-
progestogenic (OCs, progestins) environment [69e71], with sup-
pression of the adenomyotic lesion, and are frequently associated
with side effects that impact long-term use and adherence
(Table 2). Therefore, treatment should be tailored to the speciﬁc
symptom or special request of the individual patient, as severity of
pain may vary in all women with adenomyosis and more impor-
tantly, the same type of symptom may have different implications
for different women. Future research is worthwhile.Conﬂicts of interest
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